Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
TEL-AVIV, Israel, Dec. 21, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development...
-
TEL-AVIV, Israel, Dec. 20, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development...
-
The first patients have been screened and a first patient has been dosed in the open-label, dose escalation Phase Ib/II study with YELIVA® (ABC294640) for multiple myelomaThe Phase Ib/II clinical...
-
RedHill and its co-development partner, IntelGenx Corp. (IntelGenx), have signed a definitive agreement with Pharmatronic Co., granting an exclusive license to commercialize the acute migraine...
-
Following a pre-planned review of safety data, RedHill has received a unanimous recommendation from the independent Data and Safety Monitoring Board (DSMB) to continue the MAP US Phase III study...
-
Thought to be autoimmune in nature, the multiple sclerosis (MS) inflammatory process is also consistent with an infectious disease; The CEASE-MS Phase IIa proof-of-concept (PoC), single-arm,...
-
TEL-AVIV, Israel, Dec. 05, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and...
-
The poster, to be presented at the upcoming EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, describes results from non-clinical studies conducted by Apogee Biotechnology Corp....
-
TEL-AVIV, Israel, Nov. 16, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and...
-
RedHill maintains a debt-free balance sheet with $40.5 million in cash at the end of the third quarter, allowing the Company to continue to diligently execute its three ongoing Phase III...